Physician

Richard Thomas Lee, MD

According to 2025 Medicare claims, Richard Lee, MD (NPI: 1316947385) practices hematology/oncology in the Knoxville, TN market, with the plurality of this provider's patient population coming from Knox, TN. This provider's primary affiliated billing organization is TENNESSEE CANCER SPECIALISTS PLLC (NPI: 1841228871; TIN: 200677400) and primary practice location at 37909-1341.

Lee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 600 traditional Medicare patients, billed 162,656 HCPCS/CPT codes, and received $2,932,896 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,175 prescription claims across 229 beneficiaries totaling $4,872,611 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 176 records totaling $27,219. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,803,534 to $2,932,896. Similarly, Part D prescription costs have risen steadily, from $641,813 to $4,872,611. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $5,535 to $4,334.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	663	173,002	$1,803,534
2016	616	203,189	$2,103,681
2017	663	258,082	$2,452,074
2018	632	240,481	$2,746,255
2019	640	232,613	$3,710,482
2020	526	204,871	$2,883,558
2021	596	171,250	$2,279,047
2022	604	177,565	$2,847,818
2023	621	188,875	$3,122,086
2024	600	162,656	$2,932,896

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	277	1,448	$641,813
2016	262	1,489	$1,189,106
2017	285	1,983	$2,725,348
2018	283	1,815	$3,320,651
2019	272	1,691	$3,119,685
2020	251	1,359	$3,210,832
2021	296	1,416	$3,893,421
2022	262	1,155	$3,631,785
2023	230	1,063	$4,263,755
2024	229	1,175	$4,872,611

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$3,329
2016	N/R	N/R	N/R
2017	N/R	52	$2,372
2018	N/R	55	$2,620
2019	N/R	32	$2,147
2020	N/R	69	$6,075
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$985
2024	N/R	11	$1,984

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	391	684	$58
80053	Blood test, comprehensive group of blood chemicals	438	1,400	$10
36415	Insertion of needle into vein for collection of blood sample	443	1,361	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	443	1,506	$8
83615	Lactate dehydrogenase (enzyme) level	389	804	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	65	1,820	$1,303,880
Venclexta	Venetoclax	37	1,168	$470,414
Keytruda	Pembrolizumab	35	770	$385,516
Ibrance	Palbociclib	19	532	$302,317
Lenalidomide	Lenalidomide	19	532	$260,495

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4035	Enteral feeding supply kit; pump fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	N	N/R	11	$1,984

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	162	$3,501	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$23,718	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard Thomas Lee, MD?

Tedicare shows public-source Medicare data for Richard Thomas Lee, MD (NPI 1316947385), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Thomas Lee, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard Thomas Lee, MD?

Richard Thomas Lee, MD is linked to TENNESSEE CANCER SPECIALISTS PLLC (billing NPI 1841228871) in the available physician profile data.

Does Richard Thomas Lee, MD have Open Payments data?

Richard Thomas Lee, MD has 176 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.